FUJIFILM Submits Second PMA Module For Aspire Cristalle Digital Breast Tomosynthesis Option

STAMFORD, Conn.--(BUSINESS WIRE)--(Booth #4165, South Building, Hall A) – FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging products and medical informatics solutions, has submitted to the U.S. Food and Drug Administration (FDA) the second module of its premarket approval (PMA) application for digital breast tomosynthesis* (DBT), as an optional upgrade for the Aspire Cristalle mammography system. Fujifilm plans to file the remaining modules of DBT PMA within the coming year.